Epynext Therapeutics is dedicated to the development of innovative immunotherapy to fight against antibiotic resistance, one of the most urgent health threats of our time particularly in hospital settings. Epynext Therapeutics’ mission is to give inpatients infected with bacteria resistant to antibiotics an alternative therapy through targeted monodose treatments, in the form of neutralizing therapeutic monoclonal antibodies. Epynext Therapeutics is leveraging an innovative technological platform developed by Pr Jean-Luc Lenormand ,from the TIMC laboratory in Grenoble. This technological platform enables the production of therapeutic monoclonal antibodies directed against membrane antigens presented within liposomes through a cell-free protein synthesis system. Such recombinant proteo-liposomes expose all the linear and conformational epitopes of the membrane antigen, as in the pathogen. Resulting antibodies have a remarkably high affinity and specificity for their target opening the field for new applications against resistant bacteria, the first objective for Epynext Therapeutics, but also viruses or tumoral cells. A first antibody targeting Pseudomonas aeruginosa strains multi-resistant to antibiotics has demonstrated its ability to inhibit Pa both in vitro and in vivo. Originated within the University Grenoble-Alpes, Epynext Therapeutics has been supported by the SATT Linksium since 2017.
